Publications by authors named "Jetske L B Gunster"
Purpose: This study aims to identify which breast cancer patients benefit from the routine use of FDG-PET/CT in a large cohort of patients scheduled for neoadjuvant systemic therapy (NST).
Methods: A total of 1337 breast cancer patients eligible for NST were identified from a retrospective database between 2011 and 2020 at a single tertiary care hospital. All patients underwent staging with FDG-PET/CT prior to NST.
Article Synopsis
- The study evaluated cosmetic outcomes in early stage breast cancer patients using either intraoperative electron radiotherapy (IOERT) or photon external beam radiotherapy (EB-APBI) after breast-conserving surgery over a 5-year follow-up period.
- A total of 405 patients (241 treated with IOERT and 164 with EB-APBI) showed that both treatments resulted in high satisfaction rates among patients and physicians, with no significant differences in cosmetic outcomes over time.
- The conclusion indicates that both IOERT and EB-APBI provide comparable and satisfactory cosmetic results for early stage breast cancer patients, with similar ratings from both subjective and objective assessments.
Purpose: Breast cancer (BC) patients undergoing FDG-PET/CT scans for neoadjuvant chemotherapy (NAC) may have additional non-BC related findings. The aim of this study is to describe the clinical implications of these findings.
Methods: We included BC patients who underwent an FDG-PET/CT scan in our institute between 2011-2020 prior to NAC.
Objectives: To analyze the effect of percutaneous coronary intervention (PCI) before transcatheter aortic valve replacement (TAVR) on all-cause and cardiovascular mortality after TAVR, differentiating between significant proximal lesions and the non-proximal (residual) lesions.
Methods: An institutional TAVR database was complemented with data on the extent of coronary artery disease (CAD), lesion location, lesion severity, and the location of PCI. Survival analysis was performed to investigate the impact on 6-month and 3-year mortality after TAVR in all patients and in subgroups of patients with significant proximal lesions (>70% diameter stenosis [DS], >50% DS in left main), the non-proximal residual lesions, and in a propensity score matched cohort.